PARP1 and ovarian carcinoma: Cell lethality induced by PARP inhibitors in PEO1 HR-deficient ovarian cancer cells40 was also reversed by DRB, whereas HR-proficient PEO4 ovarian cancer cells, derived from the same cancer as the PEO1 cells40, were resistant to PARP inhibitors (Extended Data Fig. 7e,f).